印度保健部门在2025年的Q3交易中看到3.5B,比上季度增加了166%,其驱动因素是合并、生物技术增长和投资者的浓厚兴趣。 India's healthcare sector saw $3.5B in deals in Q3 2025, up 166% from prior quarter, driven by mergers, biotech growth, and strong investor interest.

据Grant Thornton Bharat说,印度制药和保健部门在2025年第3季度的交易活动为35亿美元,由72项交易(包括重大兼并和收购)推动的激增。 India's pharma and healthcare sector recorded $3.5 billion in deal activity in Q3 2025, a surge driven by 72 transactions including major mergers and acquisitions, according to Grant Thornton Bharat. 这一增长标志着比上个季度增加了166%,这得益于战略整合、投资者的浓厚兴趣以及非专利产品、生物技术和制造业的扩张。 The rise marked a 166% increase in value from the prior quarter, fueled by strategic consolidations, strong investor interest, and expansion in generics, biotech, and manufacturing. Torrent Pharma公司在JB Chemicals公司46%的股份中购得14亿美元,这突显了慢性护理市场的增长。 A key $1.4 billion acquisition by Torrent Pharma of a 46% stake in JB Chemicals highlighted growth in chronic care markets. 虽然私人股本投资在价值上略有下降,但保健技术和药剂服务方面的活动仍然强劲,表明印度生命科学部门持续充满信心。 While private equity investment declined slightly in value, activity remained strong in health tech and pharma services, signaling sustained confidence in India’s life sciences sector.